All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Emerging immunotherapy modalities in AML and exciting data from ASH 2019

Featured
Dec 18, 2019
Share:

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked: What are the emerging immunotherapy modalities in AML and what data from ASH 2019 is exciting in the AML immunotherapy field?

Naval Daver talks about emerging immunotherapies in the field of AML. He describes the expansion of knowledge in this field and how that has helped improve patient outcomes, such as the identification of PD-1 checkpoint as a therapeutic target and the subsequent development of therapies. He discusses studies that examine the efficacy of combination therapies, and he explains the importance of using the patient's immune profile to guide the treatment pathway.

Emerging immunotherapy modalities in AML and exciting data from ASH 2019

Share: